Lobe Sciences

(OTC) LOBEF

Current Price$0.07

Market Cap$18.86M

Since IPO (2019)-86%

5 Year-86%

1 Year+137%

1 Month+2%

Lobe Sciences last closing stock price
Metric	Price	Date
Last close	USD 0.07	2026-07-17

Lobe Sciences stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-13.9%	USD 0.08	2026-07-10
1 month	+2.12%	USD 0.07	2026-06-17
3 month	+11.71%	USD 0.06	2026-04-17
Year to date	+92.97%	USD 0.03	2025-12-31
1 year	+137.07%	USD 0.03	2025-07-17
3 year	+256.88%	USD 0.02	2023-07-18
5 year	-85.91%	USD 0.47	2021-07-16
Since inception	-86.17%	USD 0.48	2019-10-04

Lobe Sciences Financials at a Glance

Market Cap

$18.86M

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$5.62M

EPS (TTM)

-$0.02

P/E Ratio

-3.84

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$0.07

Volume

4,416

Open

$0.07

Price

$0.07

Volume

4,416

Open

$0.07

Previous Close

$0.07

Daily Range

$0.07 - $0.09

52-Week Range

$0.02 - $0.11

Estimated Earnings Date

Dec 28, 2026

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$0.07

Volume

4,416

Open

$0.07

Previous Close

$0.07

Daily Range

$0.07 - $0.09

52-Week Range

$0.02 - $0.11

Estimated Earnings Date

Dec 28, 2026

LOBEF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lobe Sciences

Lobe Sciences Ltd. is a life sciences company dedicated to researching and developing psychedelic-based medicines. The company focuses on psilocybin-derived treatments combined with N-acetylcysteine, targeting mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD).

Products and Services

Psilocybin-derived treatments for mTBI and PTSD
Specialized devices for efficient drug administration
Research and development in psychedelic medicine

Growth Outlook

Recent name change reflects a strategic focus on psychedelic therapies
Strong market potential in the growing psychedelic medicine sector
Increased research funding may enhance development capabilities

Financial Highlights

Quarterly net income of -$2,388,068 indicates ongoing investment in R&D
Cash and short-term investments of $4,960,365 provide liquidity for operations
Current ratio of 1.75 suggests a solid short-term financial position

Lobe Sciences Ltd. is positioned in a rapidly evolving sector, focusing on innovative treatments that address significant mental health challenges. The company's commitment to research and development is evident in its financials, with substantial investments aimed at advancing its therapeutic offerings. The recent quarterly results reflect a strategic emphasis on growth, despite current operating losses. The liquidity position, bolstered by cash reserves, supports ongoing operations and development initiatives. As the market for psychedelic therapies expands, Lobe Sciences Ltd. may benefit from increased interest and investment in this promising field.

AI Generated • Jul 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Frederick D. Sancilio, PhD

Website

www.lobesciences.com

Headquarters

Vancouver, BC V6E 3T5, CA

LOBEF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

4099.95%

Return on Capital

-158.97%

Return on Assets

-111.27%

Earnings Yield

-26.04%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$18.86M

Shares Outstanding

284.10M

Volume

4.42K

Avg. Volume

65.79K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$6.73M

EBITDA

-CA$6.67M

Operating Cash Flow

-CA$3.44M

Capital Expenditure

-CA$4.00

Free Cash Flow

-CA$3.44M

Cash & ST Invst.

CA$4.96M

Total Debt

CA$316.46K

Lobe Sciences Performance Analysis

Lobe Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-08-31	CAD 0	N/A
2023	2023-08-31	CAD 624,146	N/A
2024	2024-08-31	CAD 100,098	-84.0%
2025	2025-08-31	CAD 0	N/A

Lobe Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-05-31	N/A
Q4	2025-08-31	N/A
Q1	2025-11-30	N/A
Q2	2026-02-28	N/A

Lobe Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-08-31	CAD -0.25	-54.0%
2023	2023-08-31	CAD -0.03	-86.8%
2024	2024-08-31	CAD -0.03	-20.6%
2025	2025-08-31	CAD -0.02	-13.9%

Lobe Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-05-31	-34.2%
Q4	2025-08-31	-70.6%
Q1	2025-11-30	60.9%
Q2	2026-02-28	-94.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$18.86M

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-CA$1.78M

-153.6%

EBITDA

-CA$2.39M

-289.2%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

CA$4.96M

+11100.8%

Total Debt

CA$316.46K

-85.3%

Accounts Receivable

CA$20.74K

+330.7%

Inventory

CA$0.00

N/A

Long Term Debt

CA$316.46K

-79.1%

Short Term Debt

CA$0.00

-100.0%

Return on Assets

-1.11%

N/A

Return on Invested Capital

-3.12%

N/A

Free Cash Flow

-CA$2.06M

-460.6%

Operating Cash Flow

-CA$2.06M

-460.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PCLOFPharmaCielo Ltd.

PCLOFPharmaCielo Ltd.$0.04+1.69%

BBRRFBlueberries Medical Corp.

BBRRFBlueberries Medical Corp.$0.01+0.00%

BUDZWEED, Inc.

BUDZWEED, Inc.$0.03+17.00%

CVSICV Sciences, Inc.

CVSICV Sciences, Inc.$0.02+0.00%

CANNTrees Corporation

CANNTrees Corporation$0.03-7.00%

CBIHCannabis Bioscience International Holdings, Inc.

CBIHCannabis Bioscience International Holdings, Inc.$0.00+0.00%

TWSITristar Wellness Solutions Inc.

TWSITristar Wellness Solutions Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$6.53-0.02%

NFLXNetflix

NFLXNetflix$68.95-0.07%

INTCIntel

INTCIntel$95.04-0.02%

NOKNokia

NOKNokia$10.12-0.03%

NUNu Holdings

NUNu Holdings$13.59-0.01%

JOBYJoby Aviation

JOBYJoby Aviation$7.23-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.28-0.00%

Questions About LOBEF

What is the current price of Lobe Sciences?

Lobe Sciences is trading at $0.07 per share.

What is the 52-week range for Lobe Sciences?

Over the past 52 weeks, Lobe Sciences has traded between $0.02 and $0.11.

How much debt does Lobe Sciences have?

As of the most recent reporting period, Lobe Sciences reported total debt of CA$232.05K.

How much cash does Lobe Sciences have on hand?

Lobe Sciences reported CA$785.42K in cash and cash equivalents in its most recent financial results.

What is Lobe Sciences’s dividend yield?

Lobe Sciences does not currently have a dividend yield.

Lobe Sciences

Lobe Sciences Financials at a Glance

LOBEF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Lobe Sciences

LOBEF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Lobe Sciences Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About LOBEF

What is the current price of Lobe Sciences?

What is the 52-week range for Lobe Sciences?

How much debt does Lobe Sciences have?

How much cash does Lobe Sciences have on hand?

What is Lobe Sciences’s dividend yield?

Premium Investing Services